Business
Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide
Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. This major project will expand Lilly's capacity to produce oral medicines and strengthen the company's global supply chain.
About this update from Eli Lilly And Company
[{"type":"text","content":"Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain","length":133,"tagName":"p","attribs":{}},{"type":"text","content":"INDIANAPOLIS, Nov. 3, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today plans to build a new $3 billion manufacturing facility in Katwijk, the Netherlands, located within the Leiden Bio Science Park. This major project will expand Lilly's capacity to produce oral medicines and strengthen the company's global supply chain.","length":362,"tagName":"p"},{"type":"text","content":"The facility will incorporate advanced manufacturing technologies to meet the needs of Lilly's growing portfolio of oral solid medicines in cardiometabolic health, neuroscience, oncology and immunology. Innovative capabilities will include dock-to-dock automation and material flow, paperless manufacturing, process analytical technology and spray-dried dispersion, which allows oral medicines to be effectively absorbed.","length":430,"tagName":"p"},{"type":"text","content":"The new site will also be among those that will manufacture orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist. The company expects to submit orforglipron to global regulatory agencies for obesity by the end of this year.","length":246,"tagName":"p"},{"type":"text","content":""With extensive investments already underway in the U.S., our planned expansion in Europe further strengthens our ability to deliver medicines to patients worldwide. Localized manufacturing ensures we can quickly respond to meet regional demand and accelerate distribution within Europe," said David A. Ricks, Lilly chair and CEO. "Leiden Bio Science Park offers access to a skilled workforce, reliable infrastructure and proven pharmaceutical manufacturing capabilities. We look forward to working closely with the EU, national and local governments to create a more favorable and predictable policy environment open to fully harnessing innovative medicines to deliver faster access to patients."","length":717,"tagName":"p"},{"type":"text","content":"Lilly will bring 500 high-wage jobs to the South Holland province, including highly skilled engineers, scientists, operations personnel and lab technicians, who will leverage state-of-the-a...